Brian I. Rini, MD, FASCO - Optimizing Patient Outcomes in RCC Through Safe and Efficacious Use of Immuno-Oncology and Targeted Approaches: Teaming Up to Mitigate and Manage Adverse Events and Maximize Survival - a podcast by PVI, PeerView Institute for Medical Education
from 2021-05-24T18:00
Go online to PeerView.com/BZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in renal cell carcinoma discusses the latest efficacy and safety data on new treatment approaches, including tyrosine kinase inhibitors, immune checkpoint inhibitors, and novel combination approaches; applying new clinical trial evidence to the selection and sequencing of combination therapies; and mitigating and managing adverse events related to targeted and immune-based therapies to optimize outcomes. Upon completion of this activity, participants will be able to: Summarize the latest efficacy and safety data on new treatment approaches for advanced renal cell carcinoma (RCC), including tyrosine kinase inhibitors, immune checkpoint inhibitors, and novel combination approaches, Apply new clinical trial evidence to the selection and sequencing of combination therapies for individual patients with advanced RCC across lines of therapy, taking into account patient- and disease-related factors, patient values and preferences, and other considerations, Employ effective strategies to proactively mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC in order to optimize outcomes.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education